Literature DB >> 21493001

Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients.

Ethel Cesarman1.   

Abstract

Two lymphotropic human gamma herpesviruses can cause lymphoproliferative disorders: Epstein Barr virus (EBV, formally designated as human herpesvirus 4) and Kaposi sarcoma herpesvirus (KSHV, also called human herpesvirus 8). Individuals with inherited or acquired immunodeficiency have a greatly increased risk of developing a malignancy caused by one of these two viruses. Specific types of lymphoproliferations, including malignant lymphomas, occur in individuals with HIV infection, transplant recipients and children with primary immunodeficiency. Some of these diseases, such as Hodgkin's and non-Hodgkin lymphoma resemble those occurring in immunocompetent patients, but the proportion of tumors in which EBV is present is increased. Others, like primary effusion lymphoma and polymorphic post-transplant lymphoproliferative disorder are rarely seen outside the context of a specific immunodeficient state. Understanding the specific viral associations in selected lymphoproliferative disorders, and the insights into the molecular mechanisms of viral oncogenesis, will lead to better treatments for these frequently devastating diseases.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21493001      PMCID: PMC3742547          DOI: 10.1016/j.canlet.2011.03.003

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  132 in total

1.  Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus.

Authors:  H Lee; J Guo; M Li; J K Choi; M DeMaria; M Rosenzweig; J U Jung
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

Review 2.  Genetic basis of acquired immunodeficiency syndrome-related lymphomagenesis.

Authors:  G Gaidano; A Carbone; R Dalla-Favera
Journal:  J Natl Cancer Inst Monogr       Date:  1998

3.  Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP).

Authors:  Hittu Matta; Preet M Chaudhary
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-09       Impact factor: 11.205

4.  Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2.

Authors:  A G Eliopoulos; S M Blake; J E Floettmann; M Rowe; L S Young
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 5.  Manipulation of glycogen-synthase kinase-3 activity in KSHV-associated cancers.

Authors:  Masahiro Fujimuro; S Diane Hayward
Journal:  J Mol Med (Berl)       Date:  2004-01-09       Impact factor: 4.599

6.  BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome.

Authors:  E Cesarman; A Chadburn; Y F Liu; A Migliazza; R Dalla-Favera; D M Knowles
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

7.  Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex.

Authors:  M Ellis; Y P Chew; L Fallis; S Freddersdorf; C Boshoff; R A Weiss; X Lu; S Mittnacht
Journal:  EMBO J       Date:  1999-02-01       Impact factor: 11.598

8.  Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1.

Authors:  Subhash C Verma; Sumit Borah; Erle S Robertson
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice.

Authors:  W Kulwichit; R H Edwards; E M Davenport; J F Baskar; V Godfrey; N Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

10.  KSHV vFLIP is essential for the survival of infected lymphoma cells.

Authors:  Ilaria Guasparri; Shannon A Keller; Ethel Cesarman
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  86 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

2.  EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.

Authors:  Kasandra J Riley; Gabrielle S Rabinowitz; Therese A Yario; Joseph M Luna; Robert B Darnell; Joan A Steitz
Journal:  EMBO J       Date:  2012-03-30       Impact factor: 11.598

3.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

4.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

5.  Genome-wide siRNA screen for mediators of NF-κB activation.

Authors:  Benjamin E Gewurz; Fadi Towfic; Jessica C Mar; Nicholas P Shinners; Kaoru Takasaki; Bo Zhao; Ellen D Cahir-McFarland; John Quackenbush; Ramnik J Xavier; Elliott Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

6.  Type I Interferon Counteracts Antiviral Effects of Statins in the Context of Gammaherpesvirus Infection.

Authors:  Philip T Lange; Eric J Darrah; Emily P Vonderhaar; Wadzanai P Mboko; Michaela M Rekow; Shailendra B Patel; Duska J Sidjanin; Vera L Tarakanova
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

7.  Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein-Barr virus reactivation in P3HR-1 cells.

Authors:  Natacha Coen; Sophie Duraffour; Lieve Naesens; Marcela Krecmerová; Joost Van den Oord; Robert Snoeck; Graciela Andrei
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

8.  Novel gammaherpesviruses in North American domestic cats, bobcats, and pumas: identification, prevalence, and risk factors.

Authors:  Ryan M Troyer; Julia A Beatty; Kathryn R Stutzman-Rodriguez; Scott Carver; Caitlin C Lozano; Justin S Lee; Michael R Lappin; Seth P D Riley; Laurel E K Serieys; Kenneth A Logan; Linda L Sweanor; Walter M Boyce; T Winston Vickers; Roy McBride; Kevin R Crooks; Jesse S Lewis; Mark W Cunningham; Joel Rovnak; Sandra L Quackenbush; Sue VandeWoude
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

9.  B Cell-Specific Expression of Ataxia-Telangiectasia Mutated Protein Kinase Promotes Chronic Gammaherpesvirus Infection.

Authors:  Eric J Darrah; Joseph M Kulinski; Wadzanai P Mboko; Gang Xin; Laurent P Malherbe; Stephen B Gauld; Weiguo Cui; Vera L Tarakanova
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

10.  ATM facilitates mouse gammaherpesvirus reactivation from myeloid cells during chronic infection.

Authors:  Joseph M Kulinski; Eric J Darrah; Katarzyna A Broniowska; Wadzanai P Mboko; Bryan C Mounce; Laurent P Malherbe; John A Corbett; Stephen B Gauld; Vera L Tarakanova
Journal:  Virology       Date:  2015-05-21       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.